Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 07 2022 - 1:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of December 2022
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
CONTENTS
On December 7, 2022, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Announces Positive
Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy.” A copy of this press release is furnished herewith
as Exhibit 99.1 and incorporated by reference herein.
The first three paragraphs
and the section titled “Forward-Looking Statements” in the press release attached hereto as Exhibit 99.1 are incorporated
by reference into the Company’s registration statements on Form F-3 (File No. 333-266047, File No. 333-233417 and
File No. 333-248670) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: December 7, 2022 |
By: |
/s/ Oz Adler |
|
|
Name: |
Oz Adler |
|
|
Title: |
Chief Executive Officer & Chief Financial Officer |
2
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2024 to Jun 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Jun 2023 to Jun 2024